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Abstract The apolipoprotein ε4 gene allele and the apolipo-
protein E4 protein (ApoE4) are important host susceptibility
factors linked to neurocognitive disorders associated with
HIV infection or Alzheimer’s disease. Our previous studies
showed differential effects of the two most common human
ApoE genotypes, APOE3/3 and APOE3/4, on gene expression
by differentiating human neuroepithelial progenitor cells con-
tinuously exposed to HIV. To investigate the effects of ApoE3
versus ApoE4 isoforms specifically on maturing neurons, we
adapted a human neuronal progenitor cell line, hNP1, with
ApoE genotype APOE3/3. Differentiating hNP1 cells were ex-
posed for 16 days to HIV- or mock-infected supernatants and to
added recombinant ApoE isoforms rApoE3 or rApoE4 to mod-
ulate the ApoE phenotype of the cells. Gene expression was
investigated using microarray and functional genomics analy-
ses. Added rApoE3 differentially affected 36 genes. Added
rApoE4 differentially affected 85 genes; 41 of which were dif-
ferentially expressed only in HIV or mock-supernatant treated
cells, and 80% of which were downregulated. Genes differen-
tially downregulated only by rApoE4 represented multiple
neuronal functions related to neurogenesis. Approximately five
times more genes were differentially enriched by rApoE4 ver-
sus rApoE3 in the Gene Ontology (GO) cellular process anal-
ysis, with 4 orders of magnitude greater significance. Half of
the top 10 GO processes affected by rApoE4 treatment were
neurogenesis-related. The largest differences in gene expression
between the two isoforms were observed within the HIV-
exposed cultures, suggesting that HIV exposure magnifies
ApoE4’s suppressive effect on neuronal gene expression. This
study provides evidence for neuronal-specific responses to
ApoE4 that could affect neurogenesis and neuronal survival.
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Introduction
Apolipoprotein E (ApoE) is increasingly recognized as an in-
fluential if not determining host factor in neuroinflammatory
and neurodegenerative disease (Bu 2009). ApoE is a 299 amino
acid protein found in liver and brain that is important for the
transfer of cholesterol and phospholipids to cells (Mahley
1988). In the central nervous system (CNS), ApoE is synthe-
sizedmainly by astrocytes (Boyles et al. 1985; Pitas et al. 1987)
and to a much lesser extent by neurons (Xu et al. 1999). ApoE
is thought to exert its neuronal effects by binding to cell surface
receptors on the surface of neurons (Bu 2009), such that the
effects of ApoE on neurons would be largely mediated by
exogenous apolipoprotein E secreted by astrocytes.
Different protein isoforms of ApoE exist in the human
population, derived from transcription of three different al-
leles, ε2, ε3, and ε4, which contribute to the genotype (desig-
nated APOE), and have a distribution of 8%, 77%, and 15%
respectively (Mahley 1988). ApoE protein isoforms differ
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only by the presence or absence of cysteine residues in posi-
tions 112 and 158 of the protein. These seemingly small
changes nevertheless result in significant differences in the
conformation, physical properties, and biological characteris-
tics of the proteins (Hauser et al. 2011). Notably, the presence
of the APOE4 allele has been associated with a higher risk of
Alzheimer’s disease (Corder et al. 1993; Poirier et al. 1993),
with cerebrovascular disease (Frank et al. 2002), with
neuroinflammatory and neurodegenerative disease (Bu
2009), with infectious diseases such as hepatitis C and herpes
simplex (Kuhlmann et al. 2010), and with neurocognitive and
behavioral abnormalities (HAND) associated with Human
Immunodeficiency Virus (HIV) infection (Antinori et al.
2007; Clifford and Ances 2013; Saylor et al. 2016). In a
cross-sectional, observational study of 466 participants in the
CHARTER cohort (CNS HIVAntiretroviral Therapy Effects
Research), logistic regression analyses revealed no association
between APOE4 carrier status and HAND (Morgan et al.
2013). However, a clinico-pathological correlative study of
160 HIV-infected adults who received detailed clinical, neu-
ropsychological, and laboratory assessments concluded that
APOE4 and older age increased the likelihood of cerebral
amyloid-beta (Aβ) plaque deposition in HIV-infected adults
(Soontornniyomkij et al. 2012). While Aβ plaques in HIV
brains were immunohistologically different from those in
symptomatic Alzheimer’s disease brains, Aβ plaques were
associated with HAND among APOE4 carriers.
We have observed that when human neuroepithelial pro-
genitor cells (NEP) are allowed to differentiate in vitro into a
mixed population of astrocytes and neurons in the presence of
HIV, neurons “fail to thrive” (McCarthy et al. 2006; Martinez
et al. 2012; Geffin et al. 2013). There are lower total neurite
lengths per cell, and moderately decreased amounts of the
neurofilament light protein (NF-L) in HIV-exposed neurons
with the APOE3/4 genotype compared to those with the
APOE3/3 genotype (Martinez et al. 2012). These effects oc-
curred even with no apparent evidence of productive viral
infection (McCarthy et al. 2006). Changes in gene expression
in differentiated NEP cultures also occur with HIV exposure,
and this, too, is influenced by the APOE genotype of the cells.
Our previous study using gene expression microarray analysis
(Geffin et al. 2013) identified a group of genes in differentiat-
ed NEP cultures that are specifically up-regulated by exposure
to HIV virus and that are strongly related to interferon-induced
responses and antigen presentation. Differentiating NEP har-
boring the APOE3/3 genotype displayed a more robust upreg-
ulation of innate immune response genes than cells with the
APOE3/4 genotype.
While our previous study used a mixed glial and neuronal
cell population differentiated from human fetal NEP, for the
present study we have used a human neural progenitor cell
line, hNP1, to further investigate how neural cell responses to
HIVexposure are influenced by the two most common ApoE
isoforms E3 and E4, now focusing on neuronal-specific gene
expression. Although neurons are not widely productively
infected by HIV, exposure to HIV proteins can cause neuronal
toxicity and even neuronal cell death (Hesselgesser et al.
1998; Maragos et al. 2003; van Marle et al. 2004). The
hNP1 cell line, derived from the NIH-registered human em-
bryonic stem cell line WA09, has been established as a neural
progenitor line that can be differentiated into an enriched pop-
ulation of human post-mitotic neurons with functional prop-
erties such as ion channels and ionotropic receptors (Dhara
et al. 2008; Young et al. 2011; Guo et al. 2013). In the present
study, hNP1 cells were exposed to HIVSF2 MC or mock-
infected culture supernatants during differentiation in the pres-
ence of the E3 or E4 isoforms of recombinant human apoli-
poprotein E protein (rApoE). Addition of rApoE to the neu-
ronal cultures mimics the in vivo environment wherein astro-
cytes synthesize and secrete ApoE protein, which binds to
specific receptors on the neurons. Exogenous rApoE
interacting with neurons can have distinct isoform-specific
effects. In particular, rApoE4 can downregulate numerous
neuronal genes with a wide spectrum of cell functions.
Materials and Methods
Culture and Maintenance of hNP1 Cells
Proliferation hNP1 cells were obtained from Aruna
Biomedical (Athens, GA). Undifferentiated hNP1 cells were
proliferated in monolayer cultures at a density of 4.0X104
cells/cm2 in “progenitor medium” consisting of AB2™
Basal Neural Medium supplemented with 2% AB2 supple-
ment (Aruna Biomedical, Athens, GA), 1% glutamine
(Gibco ThermoFisher Scientific, Waltham, MA), and 1%
penicillin-streptomycin (GibcoThermoFisher Scientific,
Waltham, MA). Cultures were fed every 2 days and passaged
when 100% confluency was reached, or approximately once
per week.
Differentiation For differentiation into neurons, hNP1 cells
were seeded onto poly-D,L-ornithine plus fibronectin-coated
(PON-FN) coated tissue culture wells at 8.0X103 cells/cm2.
They were cultured in progenitor medium for 2 days, then
switched to sB16 differentiation medium (67% DMEM,
23% F12, 1%(w/v) bovine serum albumin, 1% penicillin-
streptomycin, 0.276%(w/v) HEPES, 1% N2 supplement, 1%
glutamine). Cultures were continued in differentiation medi-
um for up to 21 days. Real time, reverse transcription poly-
merase chain reaction (RT-PCR) detected neuronal-specific
mRNA, coding for neurofilament or microtubular proteins
that peaked by day 15 but continued elevated through day
21. Immunoblotting detected full expression of the neurofila-
ment or microtubular neuronal proteins corresponding to the
neuronal mRNA at days 15 or 21 (data not shown). Neither
mRNA nor protein for the major astrocyte intermediate fila-
ment protein, GFAP (glial fibrillary acidic protein) was detect-
ed in the lysates from differentiating hNP1 cultures at any
timepoint.
Determination of Apolipoprotein E Genotype of hNP1
cells
ApoE genotyping was performed essentially as described pre-
viously (Hixson and Vernier 1990) and adapted for these
hNP1 cultures. Genotyping is based on amplification of
APOE cellular DNA corresponding to amino acids 112
through 158. Restriction mapping of the amplified DNAwith
specific enzymes allows the discrimination of the different
isoforms (Martinez et al. 2012).
Differentiation and Culture Treatment
Twenty-four hours after the hNP1 cultures were changed to
differentiation medium, which was designated experimental
day 0, the differentiating cultures were sorted into 3 groups
of triplicate samples for three culture treatments: HIV-ex-
posed, mock-exposed, or untreated. Each culture treatment
group was further divided into 3 groups of triplicate samples
for incubation with added rApoE (E3 or E4) or no added
rApoE. Thus, each culture condition was tested in triplicate.
For all culture treatments, with and without rApoE, culture
media with additives were fully replenished every 3 days.
“HIV-Exposed” HIV-1 containing supernatants were obtain-
ed from human peripheral blood mononuclear cells (PBMC)
that were stimulated with mitogens phytohemagglutinin
(PHA, Sigma-Aldrich, St Lois, MO) and recombinant human
interleukin-2 (IL-2, Roche Diagnostics, Indianapolis, IN),
then infected with HIV-1 as described previously (McCarthy
et al. 1998). When viral concentration in the infected PBMC
supernatants was at least 100 ng/ml, the supernatants were
harvested, centrifuged at 400×g for 10 min to eliminate cellu-
lar debris, aliquoted, and frozen at -140 °C until needed.
Differentiating hNP1 cultures were exposed to HIV by
aliquoting human PBMC-derived stock virus into differentia-
tion culture medium at 20 ng p24 per 7.5X104 hNP1 cells. The
HIV-1 strain used throughout this study was obtained through
the NIH AIDS Reagent Program, Division of AIDS, NIAID,
NIH: HIV-1SF2 MC, a dual tropic strain, from Dr. Jay Levy.
This virus strain recognizes both CXCR4 and CCR5 co-
receptors for HIV binding (Trkola et al. 1998).
“Mock-Exposed” (control) Mock-exposed hNP1 cultures
were used to control for the effects of non-viral inflammatory
factors present in mitogen-stimulated PBMC supernatants
(Martinez et al. 2012). Mock-infected PBMC supernatants
were derived from PBMC stimulated with PHA and IL-2,
prepared at the same time and using the same PBMC donor
cells that were used to culture the HIV-1SF2 MC stock virus, but
never infected with HIV. Then aliquots of mock-infected
PBMC supernatant, equal in volume to the aliquots used for
HIV-1SF2 MC-infected PBMC supernatants, were added to par-
allel differentiating hNP1 cultures.
“Untreated” hNP1 cultures contained only differentiation
medium with added aliquots of PBMC growth medium
(RPMI +20% (v/v) fetal bovine serum) in the same volume
as mock-infected or HIV-infected PBMC supernatants.
Apolipoprotein E Treatment
hNP1 cells were incubated with recombinant, unlipidated hu-
man apolipoprotein E3 or E4 (Biovision Inc., Milpitas, CA)
that was diluted into the culture differentiation medium to a
final rApoE concentration of 3 μg/ml, which is the approxi-
mate concentration in the cerebrospinal fluid of normal sub-
jects (Miida et al. 1999). Both recombinant proteins were pro-
duced in E. coli, provided as lyophilized powders, and resus-
pended in water to the desired concentration, then aliquoted
and stored at -20 °C. The rApoE was replenished every three
days, simultaneously with change of culture medium and the
replenishment of HIVor mock supernatant aliquots.
Apolipoprotein E Immunoblotting
The total protein content of whole cell lysates from cell cul-
tures was determined by BCA protein assay (Pierce,
Rockford, IL) of culture lysates; between 5 and 10 μg total
protein was loaded onto 10% polyacrylamide gels.
Quantitative immunoblotting (McCarthy et al. 2006) with
chemiluminescent signal detection was used to assess ApoE
expression. ApoEwas detected with a 1:200 dilution ofmouse
monoclonal antibody (Abcam, CambridgeMA) and a second-
ary sheep anti mouse IgG diluted to 1: 2000. β actin was used
as an internal control for potential loading errors in each lane;
it was detected with an anti-β actin mouse monoclonal anti-
body (Sigma St. Louis, MO). Immunoblots were developed
with SuperSignal West FemtoMaximum Sensitivity Substrate
(Thermo Scientific, Rockford, IL). Signals were viewed and
quantitated using a Bio-Rad Chemidoc XRS+ Molecular
Imager; the ApoE signal density was normalized to beta-actin.
Immunoblotting detected endogenous ApoE in relatively
small but stable quantities at any time along the culture time-
line. Added rApoE was detected in whole cell lysates as soon
as 1 h after addition, and increased through 6 h after addition.
Retention of rApoE stabilized at 24 h after addition, and was
still detected at 72 h (data not shown). Based on this time
course, 24 h was chosen as the time lapse between the last
replenishment of rApoE (day 15 in differentiation medium)
and the harvest of cells for mRNA (day 16 in differentiation
medium).
RNA preparation and Gene Expression Microarray
Generation
hNP1 cultures were incubated in the specified culture con-
ditions for 16 days, with replenishment of culture medium
and additives at day 15. At day 16, the incubations were
terminated and cultures were lysed for preparation of RNA
for gene expression determinations. RNA was extracted
using the Illustra RNAspin Mini kit from GE Healthcare
(Pittsburgh, PA). RNA analyses and microarray data gen-
eration were performed by the technical staff of the
Oncogenomics Core Laboratory, Sylvester Comprehensive
Cancer Center (SCCC), Miller School of Medicine, and
the University of Miami.
Total RNA was quantified with a Nanodrop 8000
Spectrophotometer (Thermo Scientific, Wilmington), and its
quality was examinedwith a Bioanalyzer 2100 using the RNA
6000Nano kit (Agilent, Santa Clara, CA). Biotinylated cRNA
was prepared using the Il lumina TotalPrep RNA
Amplification Kit (Ambion, Inc., Austin, TX) according to
the manufacturer’s instructions starting with 400 ng total
RNA. Successful cRNA generation was checked using the
Bioanalyzer 2100. Samples were added to the Beadchip after
randomization using the randomized block design to reduce
batch effects. Hybridization to the Sentrix Human-HT12
Expression BeadChip (Illumina, Inc., San Diego, CA), wash-
ing and scanning were performed according to the Illumina
BeadStation 500 manual (revision C). The resulting microar-
ray data was analyzed using Illumina GenomeStudio
software.
Gene Expression Microarray Analysis
Expression data from the HumanHT-12 V4_0_R1 plat-
form array (Illumina) were loaded on GeneSpring 12.5
GX (Agilent Technologies, Santa Clara, CA, USA). The
raw data was normalized using the Quantile normaliza-
tion method and log2 transformed and scaled to median
of 0 for all samples. An unpaired Student’s t-test (for
two class comparisons) or one-way ANOVA (for
multiclass comparisons) was used to identify the signif-
icantly differentially expressed genes between the tested
conditions. The nominal p-values obtained did not pass
multiple testing corrections. Genes are considered signif-
icant if the absolute fold change differences between the
conditions were ≥1.5 and p-value (nominal) ≤ 0.05. For
ANOVA, an additional post-hoc analysis step using the
tukeyHSD method was performed to derive the most
significant differentially expressed genes. Functional en-
richment analyses of differential gene expression were
performed using the MetaCore on GeneGo program
from Thompson Reuters.
Gene Expression Validation by Quantitative RT-PCR
hNP1 monolayers were incubated in differentiation medi-
um for 16 days, then washed once with phosphate buff-
ered saline (PBS), and lysed using the Illustra RNAspin
Mini kit from GE Healthcare (Pittsburgh, PA) for RNA
extraction. RNA concentrations, 260/280, and 260/230
absorbance ratios were determined using a Nanodrop
from Thermo Scientific (Wilmington, DE). Samples were
diluted to 10 ng/μl in nuclease free water. One-step RT-
PCR reactions were carried out using a iTaq Universal
SYBR Green one step kit quantitative (qRT-PCR) from
Bio-Rad laboratories (Hercules, CA) with 50 ng of RNA
per 50 μl reaction and 400 nM of oligonucleotide primers.
All primers were synthesized by Life Technologies
(Carlsbad, CA). The qRT-PCR samples were run in a
Stratagene Mx3005P thermocycler (Agilent technologies,
Santa Clara, CA) with the following amplification condi-
tions: 51 °C for 20 min for reverse transcription, an initial
denaturing step at 95 °C for 10 min, then 40 cycles of
95 °C for 10 s and 57 °C for 30 s for annealing and
elongation. Melting curves were performed with an initial
denaturing step at 95 °C for 1 min and annealing step at
55 °C for 1 min, then increased to 95 °C for 30 s. Data
was analyzed using the MxPro software (Agilent
Technologies, Santa Clara, CA).
Target gene expression was normalized to the housekeep-
ing control gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) amplified from the same sample. Gene expression
was calculated using the ddCT method (Vandesompele et al.
2002). Three replicates of each sample were assayed, and
three independent experimental replicates of each condition
were used to estimate the expression of each gene. The mean
of normalized expression for each gene was calculated from
the three replicates. These values were then used to calculate
the mean of values for each independent experimental repli-
cate. Fold change in gene expression (rApoE added vs no
ApoE, or mock vs Unt, or HIV vs Unt) was calculated as a
direct ratio of mean gene expression values.
Representative genes chosen for validation by quanti-
tative RT-PCR were those with significant changes in
gene expression when comparing added rApoE vs no
rApoE or when comparing culture treatments (e.g.
mock-exposed vs untreated). After validation of the oli-
gonucleotide primers designed for each representative
gene, quantitative RT-PCR was performed using the same
cellular RNA specimens that were used in the microarray
analyses. Oligonucleotide primers were designed to in-
clude exon/exon boundaries on the RNA.

















Characterization of hNP1 Cultures
Human hNP1 cells are a human neural progenitor popu-
lation, derived from human embryonic stem cell line
WA09. We determined their APOE genotype to be
APOE3/3 (Materials and Methods). Undifferentiated
hNP1 cells grown in progenitor medium expressed
markers of neuronal progenitor cells, including nestin
and β-III-tubulin (Fig. 1a). With directed differentiation
using defined culture medium, the hNP1 cells generated a
mixed population of post-mitotic neurons and neuronal
lineage progenitors (Ji et al. 1998; Dhara et al. 2008).
Cells differentiated for 12 or more days in differentiation
medium expressed post-mitotic neurofilament antigens
(Fig. 1c), Hu neuronal nuclear antigen (Fig. 1d), and β-
III-tubulin along with some nestin (Fig. 1b). The principal
intermediate filament protein of astrocytes, glial fibrillary
acidic protein (GFAP), was not detected, either as mRNA
or protein, in either undifferentiated or differentiated cells.
Apolipoprotein E Uptake by hNP1 cells
ApoE was added to the cultures as a recombinant, unlipidated
form of the protein (rApoE). This approach was preferable to
other possible methods of introducing ApoE into hNP1 cells,
e.g. transfection or transduction with an ApoE-coding viral
vector. In vivo ApoE is not produced significantly by neurons,
but by astrocytes; thus addition of exogenous rApoE better
mimics the conditions found in the CNS. Introduction of
ApoE-expressing vectors during HIV exposure might change
the expression of viral genes unrelated to ApoE effects.
Moreover, unlipidated ApoE binds to Low Density
Lipoprotein Receptor-Related Protein 1 (LRP1) with higher
avidity than Low Density Lipoprotein Receptor (LDLR),
which is more prominently expressed in glia (Rebeck et al.
1993; Narita et al. 2002; Rapp et al. 2006), while LRP1 is
expressed in neurons more than LDLR.
The hNP1-derived neurons expressed endogenous
ApoE, detected as a single 34 kDa band on immunoblots
prepared from untreated or supernatant-exposed cultures
harvested after 16 days in differentiation medium (Fig. 2).
On the same immunoblots, each of the recombinant ApoE
isoform preparations migrated as a predominant 36 kDa
band and secondary 34 kDa band, best distinguished with
rApoE4 (Fig. 2), and co-migrating with the endogenous
ApoE band detected in the hNP1 cells. When hNP1-
derived neurons were differentiated with added rApoE3
or rApoE4 isoforms, immunoblotting detected 36 kDa
and 34 kDa bands corresponding to both rApoE and en-
dogenous ApoE polypeptides, with a much greater ApoE
signal in immunoblots from cells treated with rApoE3
compared to cells treated with rApoE4 or no added
rApoE. This differential accumulation of rApoE3 in
hNP1-derived neurons is consistent with previous studies
showing differential retention of ApoE3 in neurons, which
was attributed to effects mediated by cell surface heparin
sulfate proteoglycans (Nathan et al. 1995; Ji et al. 1998).
Immunoblotting demonstrated that rApoE3 and rApoE4
isoforms are bound and retained by the differentiating hNP1
neurons. Uptake of exogenous rApoE isoform E4 would ef-
fectively change the apolipoprotein E “phenotype” of the
hNP1 cells from the inherent ApoE3 to mixed ApoE3 and
ApoE4. Thus, this neuronal culture model can address: 1)
the effect of ApoE4 vs ApoE3 on maturing neuronal gene
expression, which for the purpose of this study will be referred
as the ApoE phenotype effect; and 2) the differential effect of
mock- or HIV-exposure on gene expression in these maturing
neurons within a given ApoE phenotype (Supplementary
Fig. 1).
Gene Expression Profiles of Differentiating hNP1 Cells
Exposed to rApoE: ANOVA Analysis
Nearly 48,000 probes were tested in the Illumina HT12 mi-
croarray chip. One-way ANOVA was used for multi-class
comparisons. The first one-way ANOVA comparison
(Table 1) showed that the ApoE phenotype differentially af-
fected a similar number of total genes with any culture treat-
ment (3904 for Unt, 4078 for Mock and 4070 for HIV). When
tukeyHSD post-hoc pairwise comparisons were included in
the ANOVA (Table 1), the highest numbers of genes were
differentially expressed with rApo4 treatment rather than
rApoE3 when each is referenced to no added rApoE, or when
rApoE3 is compared to rApoE4. In the pairwise comparison
42kDa
34kDa
No ApoE + rApoE3 +rApoE4
36kDa
Fig. 2 Detection of ApoE isoforms in differentiating hNP1 cells.
Differentiating hNP1 cells were exposed to medium alone (Unt), mock-
infected PBMC supernatants (Mock), and HIV-infected PBMC
supernatants (HIV), and to rApoE3 or rApoE4 at 3 μg/ml, as described
in Materials and Methods. At day 16 of differentiation, and 24 h after
replenishment of rApoE in the cultures, cells were lysed for quantitative
immunoblotting to detect ApoE. Lower blot depicts representative
endogenous ApoE detected in cell culture lysates with molecular
weight of 34 kDa, and rApoE with molecular weight of 36 kDa. Upper
blot corresponds to beta-actin used as an internal control. For comparison,
recombinant ApoE3 and ApoE4 were loaded directly on the gel at a 3 ng
per lane, as shown. Bar graphs present ApoE signal normalized to beta-
actin; each bar represents the mean of two experiments
Fig. 1 a) hNP1 cells in
proliferation media for 4 days and
immunostained with rabbit anti-
beta-3-tubulin (1:1000) (red) for
the neuronal microtubule antigen,
and mouse anti-nestin (1:200)
(green), for the neuroepithelial
progenitor intermediate filament
protein. Scale 100 μM. b) hNP1
cells in differentiation media for
12 days immunostained for rabbit
anti-beta-III-tubulin (1:1000)
(red) and mouse anti-nestin
(1:200) (green). Scale 100 μM.
hNP1 in differentiation media for
7 days immunostained with c)
rabbit anti-NFL (1:200) (red) for
the post-mitotic neurofilament
light protein (Scale 100 μM) and
d) dually stained for rabbit anti-
NFL (1:200) (red) and mouse
anti-Hu (1:200) (green), for the
nuclear neuronal protein Hu.
Scale 50 μM
of rApoE3 vs rApoE4, there was an increase in the number of
genes differentially expressed with mock-exposed or HIV-
exposed culture treatments (1158 for Unt, 1514 for Mock
and 1532 for HIV).
The second one-way ANOVA (Table 2) showed that
about 25% fewer total genes were differentially affected
by culture treatment in the presence of either rApoE com-
pared to no added rApoE. However, there was no signifi-
cant difference in the total genes when comparing rApoE3
vs rApoE4. The tukeyHSD post-hoc pairwise comparisons
showed the highest number of genes in the comparisons
between mock-exposed vs untreated or HIV-exposed vs
untreated cultures.
Gene expression Profiles of Differentiating hNP1 Cells
exposed to rApoE: Two-class comparisons and Fold
Changes
To generate differentially expressed gene profiles for each
of the rApoE isoforms in differentiating hNP1 cultures,
fold change in gene expression was calculated with added
rApoE vs no added rApoE for each of the three culture
treatments. Significantly differentially expressed genes
and their fold differences were determined by performing
a 2-class comparison between cultures with vs without
rApoE (Materials and Methods).
Effect of rApoE3
When rApoE3 was added to differentiating hNP1 cultures,
a total of 36 genes were differentially expressed (rApoE3
vs no added rApoE) when including any culture treatment
(Table 3). Only one gene, TRIM51, was differentially
expressed in common for all three culture treatments (un-
treated, mock-exposed, and HIV-exposed). TRIM51,
which was downregulated, belongs to the TRIM
(TRIpartite interaction motif) family of genes whose prod-
ucts are associated with diverse cellular functions, from
innate immune regulation (Versteeg et al. 2014) to autoph-
agy (Kimura et al. 2016). The gene for Stathmin 2
(STMN2), a nervous system protein that is upregulated
during differentiation (reviewed by (Chauvin and Sobel
2015)) was the only gene that was differentially expressed
in common between mock- and HIV-exposed cultures. The
majority of genes were differentially expressed only in
mock-exposed cultures (n = 10) or only in untreated cul-
tures (n = 20). When genes were differentially expressed in
more than one culture treatment, the direction of the
Table 1 Number of genes differentially affected by rApoE treatment (ANOVA, p ≤ 0.05)
Culture treatment tukeyHSD post-hoc pairwise comparison
Total genes E3 vs E4 E3 vs no rApoE E4 vs no rApoE
Unt 3904 1158 1741 2218
Mock 4078 1514 1754 2170
HIV 4070 1532 1558 2182
One-way ANOVAwas used to assess the differential expression of Illumina HT12 gene probes as a function of rApoE treatment. Total genes represent
the number of gene probes that are differentially affected among the three rApoE treatments (rApoE3, rApoE4, no added rApoE). This analysis was
conducted for each culture treatment. TukeyHSD post-hoc pairwise comparisons of the number of genes differentially expressed between pairs of
treatments are listed; there was little difference in the number of genes differentially expressed between rApoE4 and no added rApoE among the three
culture treatments
Table 2 Number of genes differentially affected by culture treatment (ANOVA, p ≤ 0.05)
rApoE treatment tukeyHSD post-hoc pairwise comparisons
Total genes Mock vs Unt Mock vs HIV HIV vs Unt
No added rApoE 4226 2660 1260 1854
rApoE3 3112 1477 1260 1272
rApoE4 3198 1536 1176 1497
One-way ANOVAwas used to assess the differential expression of Illumina HT12 gene probes as a function of culture treatments (untreated, mock-
exposed, HIV-exposed). Total genes represent the number of gene probes that are differentially affected among the three culture treatments in cultures
with no rApoE added, or when rApoE3 or rApoE4 were added. TukeyHSD post-hoc pairwise comparisons of the number of genes differentially
expressed between pairs of culture treatments are listed. A similar number of genes are differentially expressed in all the ApoE phenotypes when
comparing mock - vs HIV-exposed cultures
Table 3 Genes differentially regulated by rApoE3, pairwise comparisons
Genes differentially regulated in common between [HIV + rAPOE3 vs HIV], [Mock + rApoE3 VS Mock] and [Unt + rApoE3 vs Unt] n = 1
Gene ID Symbol Gene Name FC
HIV + E3 vs HIV
FC
Mock + E3 vs Mock
FC
Unt + E3 vs Unt
84767 SPRYD5 (AKATRIM51) Tripartite motif-containing protein 51 -1.7 -1.9 -1.51
Genes differentially regulated in common between [Mock + rApoE3 vs Mock] and [Unt + ApoE3 vs Unt] n = 2
Gene ID Symbol Gene Name FC
Mock + E3 vs Mock
FC
Unt + E3 vs Unt
7531 YWHAE Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein,
Epsilon
1.6 1.61
79097 TRIM48 Tripartite motif-containing protein 48 -1.8 -1.61
Genes differentially regulated in common between [HIV + rApoE3 vs HIV] and [Mock + rApoE3 vs Mock] n = 1
Gene ID Symbol Gene Name FC
HIV + E3 vs HIV
FC
Mock + E3 vs Mock
11075 STMN2 Stathmin 2 -1.54 -1.68
Genes differentially regulated in common between [HIV + rApoE3 vs HIV] and [Unt + Apo3 vs Unt] n = 2
Gene ID Symbol Gene Name FC
HIV + E3 vs HIV
FC
Unt + E3 vs Unt
6696 SPP1 Secreted phosphoprotein 1 -1.57 -1.61
4023 LPL Lipoprotein Lipase -1.61 -1.61
Genes differentially regulated only by Mock + rApoE3 vs Mock n = 10
Gene ID Symbol Gene Name FC
Mock + E3 vs Mock
26986 PABPC1 Poly(A) binding protein cytoplasmic 1 1.65
64710 LOC100130123 AKA NUCKS1 Nuclear casein kinase and cyclin dependent kinase substrate 1 1.54
729384 LOC729384 AKATRIM49D2 Tripartite motif containing 49D2 -1.5
8835 SOCS2 Suppressor of cytokine signaling 2 -1.5
642612 LOC653111 AKATRIM49C Tripartite motif containing 49C -1.52
6133 RPL9 Ribosomal protein L9 -1.53
29121 CLEC2D C-type lectin domain family 2 member D -1.54
6860 SYT4 Synaptotagmin 4 -1.55
80333 KCNIP4 Potassium voltage-gated channel interacting protein 4 -1.61
399939 LOC399939 AKATRIM49D1 Tripartite motif containing 49D1 -1.8
Genes differentially regulated only in Unt + rApoE3 vs Unt n = 20
Gene ID Symbol Gene Name FC
Unt + E3 vs Unt
1592 CYP26A1 Cytochrome P450 family 26 subfamily A member 1 1.58
56884 FSTL5 Follistatin like 5 -1.5
25897 RNF19A Ring finger protein 19A, RBR E3 ubiquitin protein ligase -1.5
1848 DUSP6 Dual specificity phosphatase 6 -1.51
5358 PLS3 Plastin 3 -1.52
51330 TNFRSF12A Tumor necrosis factor receptor superfamily member 12A -1.52
26018 LRIG1 Leucine rich repeats and immunoglobulin like domains 1 -1.54
23406 COTL1 Coactosin like F-actin binding protein 1 -1.55
214 ALCAM Activated leukocyte cell adhesion molecule -1.56
1959 EGR2 Early growth response 2 -1.56
7980 TFPI2 Tissue factor pathway inhibitor 2 -1.56
115207 KCTD12 Potassium channel tetramerization domain containing 12 -1.6
8553 BHLHB2 Basic Helix-Loop-Helix Family Member E40 -1.62
8459 TPST2 Tyrosylprotein sulfotransferase 2 -1.62
7857 SCG2 Secretogranin II -1.63
800 CALD1 Caldesmon 1 -1.64
1052 CEBPD CCAAT/enhancer binding protein delta -1.64
23180 RFTN1 Raftlin, lipid raft linker 1 -1.66
8870 IER3 Immediate early response 3 -1.7
133 ADM Adrenomedullin -1.9
AKA BHLHE40
Genes differentially regulated by HIV+ rApoE3 vs HIV n = 0
Differential gene expression was determined from comparisons between added rApoE3 and no ApoE in the three culture treatments. FC values were
calculated as described in Materials and Methods, and FC are listed if they had an absolute value of 1.5 or more and were significant with a nominal p
value of ≤0.05. Pseudogenes or discontinued probes were removed from this list. For genes with multiple probes, the FC value listed is the mean of all
absolute FC values greater or equal to 1.5
change was the same, i.e. upregulated or downregulated,
the latter being the direction for the majority (32) of differ-
entially expressed genes affected by rApoE3. The genes
differentially expressed by rApoE3 varied in their function
(Fig. 3). Prominent were cell signaling genes (e.g.
YWHAE (the only upregulated gene with this function),
SOCS2, TNFRSF12A), and seven downregulated genes as-
sociated with immune response or immunemodulation. These
included five TRIM gene family members (TRIM51, TRIM
48, TRIM49D1, TRIM49C, TRIM49D2), and two other
genes associated with immunity (SPP1 and CLEC2D). The
complete list of genes differentially expressed in the presence
of rApoE3, along with their specific functions, is in
Supplementary Table 1.
Effect of rApoE4
When rApoE4 was added to differentiating hNP1 cultures,
a total of 85 genes were differentially expressed (rApoE4
vs no added rApoE), when including any culture treat-
ment (Table 4). Of the 85 genes differentially affected
by rApoE4, only 13 were upregulated, while the majority
(72) were downregulated. The genes differentially affect-
ed by rApoE4 in any culture treatment represented func-
tions including pro-neurogenesis (n = 12), neuronal func-
tion (n = 7), cell signaling (n = 10) and enzymatic activ-
ities (n = 10), which were predominantly downregulated
(Fig. 3). Sixteen genes were differentially expressed in all
culture treatments (untreated, mock-exposed, and HIV-ex-
posed); 4 were upregulated and 12 downregulated.
Among the downregulated gene functions were cell sig-
naling (n = 3, LRIG1, IER3, RFTN1), neurogenesis
(n = 2, STMN2, MAB21L2), and neuronal function
(n = 2, SCG2, ALCAM). Twenty genes were differential-
ly expressed in common between mock- and HIV-exposed
cultures. Twelve genes were differentially expressed only
in HIV-treated cultures; all but one of these were down-
regulated. Eighteen genes were differentially expressed
only in untreated cultures, and 8 genes only in mock-
exposed cultures. The complete list of genes differentially
expressed in the presence rApoE4, along with their spe-
cific functions, is in Supplementary Table 2.
The total number of genes differentially affected by
rApoE4 (85) was more than double the number that were
differentially affected by rApoE3 (36). However, 28 of the
differentially affected genes were in common between
rApoE3 and rApoE4, and 26 of these were downregulated
genes associated with functions including cell signaling
(n = 8) and neuronal function (n = 2). There were 57
genes that were uniquely differentially expressed in the
presence of rApoE4. Of these, 13 were genes with protein
products promoting neurogenesis, and 11 were downreg-
ulated. Of the eight genes that were uniquely differentially
expressed in the presence of rApoE3, none were function-
ally related to neurogenesis, but one was associated with
neuronal function (KCNIP4).
Effect of rApoE within Culture Treatments
The rApoE4 isoform had a much greater impact than
did rApoE3 when comparing differential gene expres-
sion (i.e. rApoE vs no added rApoE) within each cul-
ture treatment (Supplementary Table 3). The difference
between rApoE3 and rApoE4 effects was most evident
in the differential gene expression associated with
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Fig. 3 Function profiles of
differentially expressed genes in
hNP1 cultures as a function of
added rApoE isoform.
Differentially expressed genes
(added rApoE3 or E4 compared
to no added rApoE with an
absolute FC value of ≥1.5 and
p ≤ 0.05) were plotted according
to their known biological
function. Included are genes with
differential expression in any
culture treatment (unt or mock or
HIV)
Table 4 Genes differentially regulated by rApoE4. Pairwise comparisons
Genes differentially regulated in common between [HIV + rApoE4 vs HIV], [Mock + rApoE4 vs Mock] and [Unt + rApoE4 vs Unt] n = 16
Gene ID Symbol Gene Name FC
HIV + E4 vs
HIV
FC
Mock + E4 vs
Mock
FC
Unt + E4 vs Unt
22915 MMRN1 Multimerin 1 1.83 1.88 1.75
83648 C8ORF13 Family with sequence similarity 167 member A
(FAM167A)
1.69 1.88 1.71
1381 CRABP1 Retinoic acid binding protein 1.60 1.61 1.89
1949 EFNB3 Ephrin B3 1.51 1.55 1.53
26018 LRIG1 leucine rich repeats and immunoglobulin like
domains 1
-1.58 -1.53 -1.58
8870 IER3 immediate early response 3 -1.62 -1.52 -1.7
7857 SCG2 secretogranin II -1.68 -1.51 -1.77
800 CALD1 caldesmon 1 -1.71 -1.53 -1.57
10586 MAB21L2 mab-21 like 2 -1.73 1.04 -1.73
214 ALCAM Activated leukocyte cell adhesion molecule -1.74 -1.56 -1.94
133 ADM Adrenomedullin -1.78 -1.55 -2.1
4023 LPL lipoprotein lipase -1.81 -1.61 -2.03
23180 RFTN1 raftlin, lipid raft linker 1 -1.81 -1.56 -1.86
40876 SYT4 synaptotagmin 4 -2.17 -2.37 -1.9
11075 STMN2 stathmin 2 -2.75 -2.73 -2.16
79097 TRIM48 tripartite motif containing 48 -2.91 -3.16 -1.82
Genes differentially regulated in common between [HIV + rApoE4 vs HIV] and [Mock + rApoE4 vs Mock] n = 20
Gene ID Symbol Gene Name FC
HIV + E4 vs HIV
FC
Mock + E4 vs
Mock
81706 PPP1R14C protein phosphatase 1 regulatory inhibitor
subunit 14C
1.80 1.73
10371 SEMA3A semaphorin 3A 1.50 1.55
27319 BHLHE22 Basic helix-loop-helix family member e22 -1.54 -1.61
3486 IGFBP3 insulin like growth factor binding protein 3 -1.54 -1.51
253738 EBF3 early B-cell factor 3 -1.56 -1.57
6422 SFRP1 secreted frizzled related protein 1 -1.56 -1.56
27065 D4S234E neuron specific gene family member 1 -1.57 -1.64
9118 INA internexin neuronal intermediate filament
protein alpha
-1.58 -1.56
4741 NEFM Neurofilament, medium polypeptide -1.61 -1.51
1282 COL4A1 collagen type IV alpha 1 chain -1.64 -1.52
8835 SOCS2 Suppressor of cytokine signaling activity 2 -1.66 -1.74
1641 DCX doublecortin -1.76 -1.83
6658 SOX3 SRY-box 3 -1.78 -1.59
729384 LOC729384 tripartite motif containing 49D2
TRIM49D2
-1.88 -2.14
63973 NEUROG2 Neurogenin 2 -1.93 -2.14
388585 HES5 hes family bHLH transcription factor 5 -1.97 -2.22
100008589 LOC100008589 RNA, 28S ribosomal 5 -2.47 1.61
642,612 LOC100134006 aka
TRIM49C
tripartite motif containing 49C -2.44 -2.63
399939 LOC399939 aka TRIM49D1 tripartite motif containing 49D1 -2.53 -2.56
84767 SPRYD5 aka TRIM51 tripartite motif-containing 51 -3.1 -3.61
Genes differentially regulated in common between [HIV + rApoE4 vs HIV] and [Unt + rApo4 vs Unt] n = 9
Gene ID Symbol Gene Name FC
HIV + E4 vs HIV
FC
Unt + E4 vs Unt
1592 CYP26A1 cytochrome P450 family 26 subfamily A
member 1
1.54 1.67
6696 SPP1 secreted phosphoprotein 1 -1.51 -1.63
51330 TNFRSF12A TNF receptor superfamily member 12A -1.53 -1.73
1278 COL1A2 collagen type I alpha 2 chain -1.55 -1.56
1363 CPE carboxypeptidase E -1.56 -1.76
56884 FSTL5 follistatin like 5 -1.59 -1.75
167681 PRSS35 protease, serine 35 -1.59 -1.91
5358 PLS3 plastin 3 -1.6 -1.64
Table 4 (continued)
115207 KCTD12 potassium channel tetramerization domain
containing 12
-1.65 -2.07
Genes differentially regulated in common between [Mock + rApoE4 vs Mock] and [Unt + rApoE4 vs Unt] n = 2
Gene ID Symbol Gene Name FC
Mock + E4 vs
Mock
FC
Unt + E4 vs Unt




26986 PABPC1 poly(A) binding protein cytoplasmic 1 -1.78 -1.65
Genes differentially regulated only by [HIV+ rApoE4 vs HIV] n = 12
Gene ID Symbol Gene Name FC
HIV + E4 vs HIV
79966 SCD5 stearoyl-CoA desaturase 5 1.7
79007 DBNDD1 dysbindin domain containing 1 -1.5
27242 TNFRSF21 TNF receptor superfamily member 21 -1.5





RN5S9 RNA, 5S ribosomal 9 -1.54
6513 SLC2A1 solute carrier family 2 member 1 -1.56
8148 TAF15 TATA-box binding protein associated factor 15 -1.56
389073 C2ORF80 chromosome 2 open reading frame 80 -1.66
2296 FOXC1 forkhead box C1 -1.67
8140 SLC7A5 solute carrier family 7 member 5 -1.72
72 ACTG2 actin, gamma 2, smooth muscle, enteric -1.78
56660 KCNK12 potassium two pore domain channel
subfamily K member 12
-1.8
Genes differentially regulated only by [Mock +rApoE4 vs Mock] n = 8
Gene ID Symbol Gene Name FC
Mock + E4 vs
Mock
653 BMP5 bone morphogenetic protein 5 1.59
7473 WNT3 Wnt family member 3 1.54
59 ACTA2 actin, alpha 2, smooth muscle, aorta -1.52
4661 MYT1 myelin transcription factor 1 -1.52
55775 TDP1 tyrosyl-DNA phosphodiesterase 1 -1.56
9208 LRRFIP1 LRR binding FLII interacting protein 1 -1.57
2674 HS.388347 GDNF family receptor alpha 1 -1.61
441087 LOC441087 uncharacterized -1.73
Genes differentially regulated only by [Unt + rApoE4 VS Unt] n = 18
Gene ID Symbol Gene Name FC
Unt + E4 vs Unt
348 APOE apolipoprotein E -1.59
794 CALB2 calbindin 2 -1.58
54769 DIRAS2 DIRAS family GTPase 2 -1.52
1848 DUSP6 dual specificity phosphatase 6 -1.60
1959 EGR2 early growth response 2 -1.77
2012 EMP1 epithelial membrane protein 1 -1.90
10912 GADD45G growth arrest and DNA damage inducible
gamma
1.54
153572 IRX2 iroquois homeobox 2 1.53
85450 ITPRIP inositol 1,4,5-trisphosphate receptor
interacting protein
-1.57
3915 LAMC1 laminin subunit gamma 1 -1.53
3988 LIPA lipase A, lysosomal acid type -1.62
Untreated
In untreated cultures, 25 genes were differentially affected by
rApoE3, with 23 of these being downregulated (Supplementary
Table 3). Eightly percent (20/25) of the differentially affect-
ed genes were also differentially affected in the same di-
rection by rApoE4 (Supplementary Table 2). About 1/3 of
the rApoE3-affected genes in untreated cultures were associat-
ed with cell signaling functions (Fig. 4). A total of 45 genes
were differentially affected by rApoE4 in untreated cultures;
18% of these (8/45) were up-regulated (Fig. 4), including 2
neurogenesis-related genes (EFNB3, IRX2) and 2 cell
signaling-related genes (FAM167A, YWHAE). Among the
differentially affected genes unique to untreated cultures,
rApoE3 and rApoE4 shared 4 genes: DUSP6, EGR2,
RNF19A, TFPI2 (see Tables 3 and 4). Shared gene RNF19A
is Ring Finger Protein 19A, RBR E3 Ubiquitin Protein Ligase.
This protein has a potential neuroprotective role, by binding to
pathogenic forms of superoxide dismutase (SOD1) variants
and targeting them for proteasomal degradation (Niwa et al.
2002). In cells treated with rApoE, this gene is downregulated
(FC −1.50 with rApoE3, FC −1.74 with rApoE4).
Mock
In mock-exposed cultures, 14 genes were differentially affect-
ed by rApoE3, with 12 of these being downregulated
(Supplementary Table 3). Ten of the 14 genes differentially
affected by rApoE3 were also differentially affected in the
same direction by rApoE4. About 40% of the rApoE3-
affected genes in mock-exposed cultures were TRIM proteins



























rApoE3 up r ApoE3 down rApoE4 up r ApoE4 down
Untreated cultures
Fig. 4 Function profiles of
differentially expressed genes in
untreated cultures with added
rApoE. Differentially expressed
genes (added rApoE3 or E4
compared to no added rApoE
with an absolute FC value of ≥1.5
and p ≤ 0.05) were plotted
according to their known
biological function
Table 4 (continued)
4627 MYH9 myosin, heavy chain 9, non-muscle -1.52
10455 PECI enoyl-CoA delta isomerase 2 -1.50
5730 PTGDS prostaglandin D2 synthase -1.54
5764 PTN pleiotrophin -1.62
25897 RNF19A ring finger protein 19A, RBR E3 ubiquitin
protein ligase
-1.74
6464 SHC1 SHC adaptor protein 1 -1.52
7980 TFPI2 tissue factor pathway inhibitor 2 -1.69
Differential gene expression was determined from comparisons between added rApoE4 and no ApoE in the three culture treatments. FC values were
calculated as described in Materials and Methods, and FC are listed if they had an absolute value of 1.5 or more and were significant with a nominal p
value of ≤0.05. Pseudogenes or discontinued probes were removed from this list. For genes with multiple probes, the FC value listed is the mean of all
absolute FC values greater or equal to 1.5
rApoE4 in mock-exposed cultures; 19% of these (9/47) were
up-regulated (Fig. 5), including 3 cell signaling-related genes
(FAM167A, YWHAE, WNT3). Among the differentially af-
fected genes unique to mock-exposed cultures, rApoE3 and
rApoE4 did not share any genes.
HIV
In HIV-exposed cultures, rApoE4 had an almost exclusive
effect on gene expression, as compared to rApoE3
(Supplementary Table 3, Tables 3, 4). Only 4 genes were
differentially affected by rApoE3 (Supplementary Table 3,
Table 3, Fig. 6); all of these were downregulated, and all 4
genes were also differentially affected in the same direction
by rApoE4 (Supplementary Table 3, Table 4). A total of 57
genes were differentially affected by rApoE4 in HIV-
exposed cultures, which was the highest number of genes
affected by rApoE in any of the culture treatments. Twelve
percent of these (7/57) were up-regulated, including 2 neu-


















rApoE3 up rApoE3 down rApoE4 up rApoE4 down
Mock-exposed cultures
Fig. 5 Function profiles of
differentially expressed genes in
mock-exposed cultures with
added rApoE. Differentially
expressed genes (added rApoE3
or E4 compared to no added
rApoE with an absolute FC value
of ≥1.5 and p ≤ 0.05) were plotted





















rApoE3 up rApoE3 down rApoE4 up rApoE4 down
HIVSF2 MC-exposed cultures
Fig. 6 Function profiles of
differentially expressed genes in
HIV-exposed cultures with added
rApoE. Differentially expressed
genes (added rApoE3 or E4
compared to no added rApoE
with an absolute FC value of ≥1.5
and p ≤ 0.05) were plotted
according to their known
biological function
genes genes coding for enzymes (CYP26A1, SCD5)
(Fig. 6). Twenty one percent (12/57) of the genes differen-
tially affected by rApoE4 in HIV-exposed cultures were
unique to HIV-exposure; these 12 genes represented a va-
riety of cell functions, and all but one were downregulated
(Table 4, Fig. 6).
Effect of Mock- or HIV-Exposure on Differential Gene
Expression: Pairwise Comparisons
To look for genes that are impacted by culture treatment but
not by ApoE phenotype, gene expression in mock-exposed or
HIV-exposed cultures was compared by Student’s t-test to that
of the same gene in untreated cultures. Then differential gene
expression was calculated as a FC, which represents the ratio
of a gene’s expression in mock-exposed vs untreated or HIV-
exposed vs untreated hNP1 cultures. Genes with FC having
nominal p value ≤0.5 and absolute FC value ≥1.5 were iden-
tified, and then categorized for function.
Among all ApoE phenotypes, including hNP1 cultures
without any added rApoE, 4 genes are upregulated in common
by mock supernatant exposure as compared to untreated
(B2M, STAT1, TAP1, KCNIP4), and 1 gene is upregulated
in common by HIV exposure as compared to untreated
(KCNIP4). Thus, 4 genes are upregulated in hNP1-derived
neurons exposed to mock- or HIV-supernatants, regardless
of ApoE. The ubiquitous KCNIP4 gene encodes a voltage-
gated potassium (Kv) channel-interacting protein which reg-
ulates neuronal excitability in response to changes in intracel-
lular calcium. Two of these consistently upregulated genes,
B2M (beta-2-microglobulin) and STAT1, were significantly
upregulated (p ≤ 0.05) in HIV-exposed mixed astrocyte and
neuron cultures differentiated from human NEP, regardless of
ApoE genotype (Geffin et al. 2013). Both B2M and STAT1
are reportedly upregulated in transcriptomes fromNeuroAIDS
brain (Winkler et al. 2012). Thus, these hNP1-derived neurons
identify at least 2 common neuronal-specific gene responses
to HIVexposure.
Functional Enrichment Analyses
For these analyses, the input gene sets were the differentially
expressed genes derived from the pairwise comparison of
gene expression with added rApoE vs no added rApoE in
untreated, mock-exposed, or HIV-exposed cultures.
Enrichment pathway analysis found no enriched canonical
pathways for genes differentially affected by rApoE3 with
absolute FC value of 1.5 or more, regardless of culture treat-
ment. Enrichment analysis for GO (Gene Ontology) cellular
processes for the same rApoE3-related input gene sets re-
vealed a small number of genes in each GO cellular process
that was found to be enriched, as compared to the total number
of genes participating in the pathway (Fig. 7). The top 10most
significant GO cellular processes affected by rApoE3 include
regulation of neuron differentiation, and intrinsic apoptotic
signaling pathway. However, the most significant p value
was 1.131 × 10−05 FDR 1.234 × 10−03 for the top GO process
(regulation of neuron differentiation) comparing mock cul-
tures with added ApoE3 vs mock cultures without added
ApoE. Four of the top 10 GO processes in this analysis were
related to neuronal lineage cells and were most significantly
enriched by rApoE3 in mock-exposed cultures: regulation of
neuron differentiation, regulation of neurogenesis, positive
regulation of neuron differentiation, regulation of nervous sys-
tem development. A list of GO processes affected by rApoE3
as well as the genes enriched in these processes is located in
Supplementary Table 4.
Functional enrichment pathway analysis identified a
number of canonical pathways for genes that were signif-
icantly differentially affected by rApoE4 with absolute FC
of 1.5 or more. Again, a small number of genes signifi-
cantly enriched the identified pathways for each of the
culture treatments, and p values ranged from the order
of 10−1 to 10−5 (data not shown). Only one of the top
10 enriched pathways involved neuronal function.
However, when the GO cellular processes were examined
with the same input gene sets, a larger number of genes
differentially affected by rApoE4 were in data for each
process (Fig. 7). Of the top 10 GO cellular processes
enriched by rApoE4-affected genes in all three culture
treatments, at least 5 directly involve neuronal develop-
ment. These included nervous system development and
brain development (the top 2 processes) and head devel-
opment, generation of neurons, and neurogenesis. The p
value for the most significant process (nervous system
development) was 6.13 × 10−13, FDR 1.73 × 10−9 found
with the differentially affected genes in mock-exposed
cultures. In all of the top 10 GO cellular processes, the
p values were consistently more significant with genes
differentially affected by rApoE4 in mock-exposed and
HIV-exposed cultures, while p values were less significant
with genes in untreated cultures (Fig. 7). The genes ac-
tively participating in these neuronal-related processes
were most often downregulated, and these downregulated
genes have functional significance for neurogenesis and
Fig. 7 GO processes enriched by added rApoE3 (upper panel) or
rApoE4 (lower panel) when comparing untreated, mock and HIV-
treated cultures. The input gene sets were the differentially expressed
genes derived from the pairwise comparison of gene expression with
added rApoE vs no added rApoE in untreated, mock-exposed, or HIV-
exposed cultures; the differentially expressed genes had absolute FC
values of 1.5 or more, and nominal p value of ≤0.05. Top 10 GO
processes are listed with the number of genes participating in the
process and the –log p value of their significance. The names of the
processes and the total number of genes in the process are listed in the
text boxes below each panel
neuronal growth (Supplementary Table 5). For example,
in HIV-exposed cultures, 36 genes were found to be
enriched in the “nervous system development” GO
process. Of these 36 genes, at least 20 were downregulat-
ed (Supplementary Table 5). These genes include SOCS2,
Adrenomedullin, STMN2, Synaptotagmin, Neurofilament-M,
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Doublecortin, and Neurogenin2, among others. The function-
al enrichment analysis by GO process yielded results that are
consistent with the results obtained from gene expression pro-
files (Fig. 3), i.e. neurogenesis and neuronal-related genes that
are differentially affected by rApoE4 tend to be downregulat-
ed. A detailed list of GO processes enriched by rApoE4 is
located in Supplementary Table 5.
Parallel functional enrichment analyses were also per-
formed to compare the effect that rApoE4 vs rApoE3 treat-
ment have on the enrichment of GO processes in the context
of the individual culture treatment. For these comparisons, the
input gene sets were the differentially expressed genes derived
by the pairwise comparison of rApoE (E3 or E4) vs no added
rApoE in a single culture treatment. The selected genes had an
absolute FC value of 1.2 or more and nominal p values of less
than 0.05. Gene Ontology (GO process) analyses revealed
significant differences in the way the two rApoE isoforms
affect the functional enrichment by GO process within each
culture treatment (Figs. 8a-c). In general, for all culture treat-
ments, a larger number of genes enriched the top ten GO
processes with rApoE4 treatment. This difference between
rApoE4 and rApoE3 in the number of genes affecting the
GO processes was more pronounced for cultures exposed to
HIV (Fig. 8a). Approximately 4–7 fold more genes affected
the top 10 GO processes when rApoE4 was added than
rApoE3. For mock-exposed and untreated cultures, the differ-
ences between the two rApoE isoforms was approximately
two-fold (Figs. 8b, c). The p values for all three culture treat-
ments were very significant (between 2 × 10−34 to 4 × 10−16),
but the lowest (most significant) were found for the enrich-
ment GO processes related to HIV exposure and addition of
rApoE4. For the three culture treatments, nervous system
development was consistently among the top ten GO pro-
cesses. More GO processes related to neuronal develop-
ment, including neurogenesis and generation of neurons,
were among the top 10 GO processes detected for the
mock-exposed and HIV-exposed cultures, but not for un-
treated cultures. Other processes not specifically related to
neurogenesis were also affected preferentially by rApoE4
in all three culture treatments, processes such as system
development, single multicellular organism process, and
multicellular organism development. Among the 26 genes
affecting the top GO process (nervous system develop-
ment) when rApoE3 is added in the context of HIV expo-
sure, 21 are also found among the 138 genes enriching this
GO process when ApoE4 is added, and the direction in
which these common genes are differentially affected is
also the same. Of the remaining 117 genes that affect the
nervous system development GO processes and that are
unique to ApoE4, the majority (approximately 75%) are
downregulated. A list comparing GO process genes
enriched by rApoE3 vs rApoE4 in the different culture
treatments is located in Supplementary Table 6.
Confirmatory RT PCR of Differentially Regulated Genes
Quantitative RT PCR was used to independently confirm the
differences in gene expression obtained with microarray anal-
ysis of hNP1 cultures. Representative genes were selected to
validate changes in gene expression as a consequence of
rApoE addition to the cultures, or as a consequence of culture
treatment with mock-infected or HIV-infected PBMC super-
natants. Representative genes, reflecting the differential effect
of rApoE3, rApoE4, or both, included: PABPC1, which en-
codes a protein involved in RNA metabolism; ALCAM, im-
portant for neurite extension; TRIM48, one of the TRIM fam-
ily of proteins; and neurofilament medium polypeptide
(NEFM), a post-mitotic intermediate filament protein of neu-
rons (Table 5). Representative genes reflecting the effects of
mock- or HIV exposure on differentiating hNP1 cells regard-
less of ApoE phenotype included: beta-2-microglobulin
(B2M), and STAT1 (Table 6). Results obtained by the two
methods, expressed as fold change in gene expression
(Tables 5 and 6), were comparable, and indicate a close agree-
ment between gene expression determined by microarray and
by RT-PCR assays.
Discussion
In this study, mock- or HIV-exposed neuronal lineage
cells were differentiated directly from the human neural
progenitor cell line hNP1 in the presence of recombi-
nant ApoE3 or ApoE4 isoforms in order to examine the
effect of ApoE phenotype on neuronal gene expression.
These hNP1-derived neuronal cultures lack a GFAP-
expressing astrocyte sub-population, so the observed dif-
ferential gene responses to HIV exposure or to ApoE
isoforms represent neuronal-specific responses. The
hNP1-derived neurons, with an inherent APOE3/3 geno-
type, produce detectable but low amounts of endoge-
nous ApoE, characteristic of neurons. But these cells
take up and retain rApoE3 or rApoE4 isoforms readily
when rApoE is added to cultures in μg/ml concentra-
tions, mimicking what neurons do in vivo when ApoE
is secreted by astrocytes. The ApoE phenotype of the
hNP1-derived neurons was thus affected by the added
rApoE isoform, and differences in gene expression were
observed accordingly, with both fold change values and
functional genomics analyses. Addition of rApoE3 re-
sulted in the differential expression of 36 genes, while
addition of rApoE4 was remarkable in both the number
of genes that were differentially regulated (85, more
than double than rApoE3) and in the negative direction
of the regulation. A suppressive effect of rApoE4 was
demonstrated with downregulation of 72 of the 85 dif-
ferentially expressed genes. Of these, 19 coded for
proteins associated with neurogenesis and neuronal
functions. Differences in gene expression between
rApoE3 and rApoE4 were more pronounced in mock-
or HIV-exposed compared to untreated hNP1 neurons.
This suggests that mitogens or factors released by stim-
ulated PBMC (Martinez et al. 2012) may affect the in-
teraction between rApoE3 or rApoE4 isoforms and
hNP1 neurons. However, the most striking differences
HIV +ApoE4 vs no ApoE
HIV+ApoE3 vs no ApoE
GO process  Total number of genes
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Fig. 8 GO processes enriched when comparing the effect of rApoE3 or
rApoE4 within each culture treatment. The input gene sets were the
differentially expressed genes derived from the pairwise comparison of
gene expression with added rApoE vs no added rApoE in HIV-exposed
(Fig. 8a), mock-exposed (Fig. 8b), or untreated (Fig. 8c) cultures with
absolute FC values of 1.2 or more, and nominal p value of ≤0.05. Top 10
GO processes are listed with the number of genes participating in the
process and the –log p value of their significance. The names of the
processes and the total number of genes in the process are listed in the
text boxes to the right of each panel
in gene expression between rApoE3 and rApoE4 were
observed in HIV-exposed hNP1 neurons (4 genes
differentially regulated by rApoE3 compared to 57
genes by rApoE4). Enrichment analysis of the differen-
tially expressed genes also found that the number of
genes enriching the Gene Ontology (GO) processes
was highest in cultures exposed to HIV and with added
rApoE4 compared to added rApoE3. For each of the
culture treatments (untreated, mock-exposed, HIV-ex-
posed), both the number of genes enriching the GO
cellular processes and the p value of the effect on the
biological process were more significant for cultures
with rApoE4 than for cultures with rApoE3. These dif-
ferential effects suggest an additive or synergistic inter-
action between ApoE4 and HIV.
Both this study and our previous study (Geffin et al. 2013)
have endorsed a suppressive effect of ApoE4 on neural gene
expression, particularly in HIV-exposed cells. In our previous
study, human fetal NEP-derived cultures of mature astrocytes
and post-mitotic neurons with the APOE3/3 genotype upreg-
ulated innate immune response genes when exposed to HIV.
Most of these genes were interferon-related. However, HIV-
exposed cultures harboring the APOE3/4 genotype had dimin-
ished innate immune gene responses, with at least 50% fewer
genes enriched in the top 10 GO cellular processes. Given the
known immune reactive capacity of astroglia (Liddelow and
Hoyer 2016), it is likely that the astrocyte sub-population with
the APOE3/4 genotype was the predominant source of the
differentially suppressed immune-related gene responses.
The astrocytes would also be the principal source of secreted
ApoE3 or ApoE4 that binds to specific neuronal surface re-
ceptors. In the current study, the hNP1 cultures lack GFAP-
expressing astrocytes, and the source of “secreted” ApoE is
added exogenous rApoE. When rApoE4 was added to hNP1
neurons, the ApoE phenotype was effectively changed from
the inherent ApoE3 to predominantly ApoE4. The greatest
impact of the change to an ApoE4 phenotype was observed
in the HIV-exposed cultures (Fig. 8a), where most of the genes
enriching the GO cellular processes were downregulated.
Functional genomics analysis also highlighted the suppressive
impact of ApoE4 on the expression of numerous genes asso-
ciated with neurogenesis, neuronal structure or function, or
immune responses. Five genes that were uniquely downregu-
lated by rApoE4 code for transcriptional factors that promote
neurogenesis (EBF3, MYT1, FOXC1, NEUROG2,
BHLHE22). Other downregulated genes code for structural
proteins characteristic of mature neurons (DCX, NEFM,
INA), growth factors (PTN) and neurotrophic factors
(HS.388347).
Apolipoprotein E, particularly the APOE4 allele or the
ApoE4 protein isoform, is one of the most significant of
known host factors influencing neurodegenerative or inflam-
matory disorders (Frank et al. 2002; Jahanshad et al., 2012),
particularly in older affected individuals (Pomara et al. 2008;
Mukerji et al. 2016; Wendelken et al. 2016). Multiple
Table 5 FC values obtained by RT PCR versus gene expression
microarray for genes differentially expressed with rApoE treatment
RT PCR MICROARRAY
PABPC1 Mock E3 -1.18 -1.32
Mock E4 -1.34 -1.42
Unt E4 -1.10 -1.34
ALCAM Unt E3 -1.13 -1.56
HIV E4 -1.43 -1.74
Mock E4 -1.33 -1.56
Unt E4 -1.37 -1.95
YWHAE Mock E3 -1.14 1.38
Unt E3 1.34 1.22
Mock E4 -1.10 1.26
Unt E4 1.22 1.54
TRIM48 Mock E3 -3.53 -1.81
Unt E3 -1.99 -1.61
HIV E4 -3.18 -2.91
Mock E4 -4.25 -3.16
Unt E4 -1.72 -1.82
NEFM HIV E4 -2.00 -1.62
Mock E4 -1.61 -1.52
Genes found to be differentially expressed with rApoE treatment as de-
termined by gene expression microarray were then tested for differential
expression by RT PCR of the same cellular RNA. FC values were derived
from comparison of gene expression with rApoE vs no rApoE. The mi-
croarray FC value listed for PABPC1 represents the mean of 5 probes and
for YWHAE is the mean of 3 probes
Table 6 Comparison of FC values obtained by RT PCR and by gene
expression microarray
Gene rApoE treatment Culture treatment RT PCR Microarray
B2M No rAPOE HIV vs Unt 1.43 1.42
Mock vs Unt 2.17 1.83
rAPOE3 added HIV vs Unt 2.04 1.85
Mock vs Unt 1.91 1.90
rAPOE4 added HIV vs Unt 1.80 1.57
Mock vs Unt 1.92 1.93
STAT1 No rAPOE HIV vs Unt 1.50 1.26
Mock vs Unt 2.10 1.52
rAPOE3 added HIV vs Unt 2.11 1.33
Mock vs Unt 2.09 1.57
rAPOE4 added HIV vs Unt 1.76 1.30
Mock vs Unt 1.77 1.52
Genes found to be differentially regulated by culture treatments detected
using gene expression microarray were tested for their expression using
RT PCR. FC values are listed for each culture treatment comparisons. FC
values listed for microarray analysis for both genes are the average of
more than one probe
experimental reports have expanded on the observed neuro-
logical consequences of harboring the APOE4 allele or the
ApoE4 isoform. In ApoE-targeted replacement (TR) mice,
dendritic spine density is lower in ApoE4 than in ApoE3
and ApoE2 TR mice (Nwabuisi-Heath et al. 2014). Neurons
synthesize ApoE when subjected to stress, and the results may
be injurious, especially with ApoE4 (Mahley et al. 2009).
After traumatic brain injury (TBI), rodents expressing the hu-
man ApoE4 protein die more often, and those who survive do
worse in cognitive tests and measurements of neurite growth
compared to mice expressing the human ApoE3 protein or no
human ApoE (Buttini et al. 1999; Sabo et al. 2000). After TBI
induced by controlled cortical impact, ApoE3 and ApoE4
transgenic mice showed differences in gene expression pro-
files from both cortex and hippocampus (Crawford et al.
2009). The observed differences in gene expression predicted
functional consequences related to inflammatory responses,
cell growth, and cell signaling, and suggested a “loss of repar-
ative function rather than a gain of negative function” in the
presence of ApoE4 (Crawford et al. 2009).
Diverse molecular mechanisms have been postulated for
ApoE’s effects, ranging from direct transcriptional repression
(Theendakara et al. 2016) to facilitating amyloid plaque de-
velopment in damaged neurons (Bu 2009). In a study using
human neuroblastoma and human glioblastoma cells, trans-
fection with ApoE3 and ApoE4 expression vectors revealed
differential and repressive effects of ApoE4 on gene transcrip-
tion (Theendakara et al. 2016). Application of ChIP-seq to
assess ApoE3 and ApoE4 binding on a genome-wide scale
identified four genes (sirtuin1, MADD, ADNP, COMMD6) in
which ApoE4 interacted with the promoter, reduced transcrip-
tion, and reduced mRNA levels. This indicated a capacity for
ApoE4 to function as a transcriptional repressor. None of the
ApoE4-affected genes identified in that study overlapped with
the differentially expressed genes in our study. This is consis-
tent, though, with distinct differences in the cells tested (glial-
derived vs neuronal lineage) and the modes of ApoE delivery.
These differences lead to relevant but distinct outcomes.
However, our studies have a common strategy of altering the
ApoE phenotype in human neural cells in culture, and a com-
mon outcome of observing depressed differential gene expres-
sion associated with the ApoE4 phenotype compared to the
ApoE3 phenotype.
The influence of ApoE4 on HAND is controversial. Recent
published studies of HIV-infected cohorts found no associa-
tion between the severity of cognitive impairment and APOE
genotype (Morgan et al. 2013; Becker et al. 2015), and no
association between APOE4 genotype and poorer neuroimag-
ing outcomes, even when stratified by age (Cooley et al.
2016). However, other studies have associated APOE4 geno-
type with faster HIV-1 disease progression (Burt et al. 2008),
or with decreased cognitive executive functioning in older
HIV-infected individuals (Wendelken et al. 2016). Moreover,
higher CSF ApoE levels reportedly associated with poorer
cognitive performance in a “dose-dependent” manner in
HIV-infected APOE4 carriers (Andres et al. 2010). In a study
including 70 seronegative and 69 HIV seropositive subjects
(Chang et al. 2011), the APOE4 allele exhibited antagonistic
pleiotropy on cognition and brain volume in seronegative con-
trols, with a positive effect on younger and negative effect on
older subjects. But the younger HIV-infected APOE4 carriers
showed poorer cognition and smaller brain volumes. A sub-
sequent study of glial metabolites expanded on this APOE4
allele effect. A study of 177 individuals, including 80 HIV
seropositives, found that myo-inositol levels in frontal white
matter increased with age in seronegative subjects, more
steeply in APOE4 carriers. But levels were elevated regardless
of age in HIV-infected individuals, suggesting that persistent
glial activation due to HIV infection offsets the antagonistic
pleiotropy of APOE4 (Chang et al. 2014).
The findings in this study suggest there is an interaction
between ApoE4 and HIV exposure in neurons. Among the
three culture treatments, rApoE4 has the greatest differential
effect on gene expression in HIV-exposed hNP1 neurons, and
most of the differentially expressed genes are downregulated.
While rApoE4 has a largely downregulatory effect on gene
expression with all culture treatments, HIV exposure mag-
nifies this effect to a higher number of genes. In that rApoE4
can enhance HIV-target cell fusion (Burt et al. 2008), hNP1
neurons treated with rApoE4 may be binding HIVSF2 MC to a
greater extent than neurons treated with rApoE3, thus intensi-
fying the effects that HIV exposure has on neuronal gene
expression. Addition of rApoE4 at 10μg/ml to HIV target
cells has been shown to increase their susceptibility to HIV
infection, while addition of rApoE3 reduces it (Burt et al.
2008). This is due to a higher frequency of HIV-target cell
fusion, and occurs using either CXCR4 or CCR5-tropic virus.
This suggests a direct or indirect interaction between the virus
and ApoE or the ApoE receptor that is isoform sensitive.
ApoE4 may increase neuronal susceptibility to toxic effects
(e.g. depressed mitochondrial membrane potential) after ex-
posure to HIV-1 tat or gp120 proteins (Turchan-Cholewo et al.
2006). Indeed, tat protein, binds to neuronal LRP1, which can
inhibit uptake and clearance of ApoE4 as well as amyloid
precursor protein (Liu et al. 2000), effectively prolonging their
circulation in the neuron’s microenvironment. Collectively,
these results suggest that ApoE4may have a detrimental effect
on neurons that synergizes with HIV infection.
This study has limits posed by certain constraints inherent
in the cell culture model. The neuronal population differenti-
ated from the hNP1 cell line may be a mixture of cells with
varying levels of differentiation. Therefore, there may be ad-
ditional influences of neuronal maturation on differential gene
expression in response to ApoE4 and HIVexposure. The lack
of astrocytes does limit detection of the full range of potential
effects that ApoE isoforms might exert on neurons by
eliminating any astrocyte-mediated interactions. But in this
study, the neuronal setting provides the advantage of manip-
ulating only the ApoE phenotype in neurons, and determining
differentially expressed genes specific to neurons, without
other confounding factors. Microarray and functional geno-
mic studies also have inherent limitations in the algorithms
and databases used to probe gene expression, and to define
the metabolic pathways and cellular processes enriched by the
differentially affected genes.
Our current study with the human hNP1 neural progenitor
cell line, along with previous studies using human NEP-
derived mixed neuronal and astrocyte cultures (Martinez et al.
2012; Geffin et al. 2013), add to the evidence for the suppres-
sive effect of ApoE4 on neural gene expression, an effect that is
magnified in cells exposed to HIV. The response to ApoE4 can
be neuronal-specific; astrocytes do not need to be present to see
suppressive changes in neuronal gene expression. In the con-
text of HIV infection, ApoE4 can differentially suppress gene
expression in cellular processes that impact neurogenesis and
neuronal survival.
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